title: Pregnancy reduces brain sigma receptor function.
abstract: 1. Sigma (sigma) receptors have recently been cloned, though their endogenous ligand(s) remain unidentified. However, some neuroactive steroids, such as progesterone, have a high affinity for these receptors. Some sigma ligands, such as DTG, (+)-pentazocine and DHEA, act as sigma 'agonists' by potentiating the neuronal response to NMDA. Others, such as haloperidol, NE-100 and progesterone, act as sigma 'antagonists' by reversing the potentiations induced by sigma 'agonists'. 2. We compared the effects of sigma 'agonists' in four series of female rats: in controls, at day 18 of pregnancy, at day 5 post-partum, and in ovariectomized rats following a 3-week treatment with a high dose of progesterone. 3. In pregnant rats and following a 3-week treatment with progesterone, 10 fold higher doses of DTG, (+)-pentazocine and DHEA were required to elicit a selective potentiation of the NMDA response comparable to that obtained in control females. Conversely, at day 5 post-partum and following the 3-week treatment with a progesterone and after a 5-day washout, the potentiation of the NMDA response induced by the sigma 'agonist' DTG was greater than in control females. 4. The present data suggest that endogenous progesterone acts as an 'antagonist' at sigma receptors. The resulting changes in the function of sigma receptors during pregnancy and post-partum may be implicated in emotional phenomena occurring during these periods.
authors.affiliation: Neuroscience Laboratory, Department of Psychiatry, Harvard Medical School, 940 Belmont Street, Brockton, MA, 0230 USA.
authors.forename: R
authors.initials: R
authors.lastname: Bergeron
authors.forename: C
authors.initials: C
authors.lastname: de Montigny
authors.forename: G
authors.initials: G
authors.lastname: Debonnel
mesh_terms: D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D003687:Dehydroepiandrosterone / Q000494:pharmacology*; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology; D010052:Ovariectomy; D010423:Pentazocine / Q000494:pharmacology*; D049590:Postpartum Period / Q000187:drug effects / Q000502:physiology; D011247:Pregnancy; D011374:Progesterone / Q000097:blood / Q000494:pharmacology; D017966:Pyramidal Cells / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000502:physiology; D017480:Receptors, sigma / Q000187:drug effects* / Q000502:physiology
chemical_list: D000276:Adjuvants, Immunologic; D000701:Analgesics, Opioid; D000927:Anticonvulsants; D006146:Guanidines; D016194:Receptors, N-Methyl-D-Aspartate; D017480:Receptors, sigma; D003687:Dehydroepiandrosterone; D011374:Progesterone; C050232:1,3-ditolylguanidine; D010423:Pentazocine